Financial
Part of RadNet (RDNT).
Latest full-year results not yet captured by HSH.
iCAD
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Not assessed
Customer rating
No reviews yet
Financial health
Band: Not assessedOwned by RadNet (RDNT)
Part of RadNet (RDNT).
Latest full-year results not yet captured by HSH.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Aug 2025: RadNet's subsidiary DeepHealth completed its acquisition of iCAD, folding iCAD's business, technology and regulatory functions into DeepHealth; buyers should note the change of ownership.
Cyber & information governance
No data breaches, cyber incidents or regulator action involving iCAD found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
No recalls, FDA/MHRA safety notices or warning letters involving iCAD or its ProFound AI products found in HSH's search of the last 24 months.
Contract performance
No notable go-lives, troubled implementations, terminations or significant NHS contracts involving iCAD found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.